Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE